Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 studyArjun Vasant Balar, Ronald de Wit, Ashish M. Kamat et al.|The Lancet Oncology|2021Cited by 532
Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspectiveJeremy Yuen‐Chun Teoh, Marek Babjuk, Ashish M. Kamat et al.|Nature Reviews Urology|2022Cited by 196
1,1-Bis(3′-indolyl)-1-( <i>p</i> -chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growthTeruo Inamoto, Ashish M. Kamat|Molecular Cancer Therapeutics|2008Cited by 104
Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosisGoodwin G. Jinesh, Ashish M. Kamat|Cell Death and Differentiation|2012Cited by 58
International Society of Urological Pathology Expert Opinion on Grading of Urothelial CarcinomaTheodorus van der Kwast, Liang Cheng, Bas W.G. van Rhijn et al.|European Urology Focus|2021Cited by 45